EXELA Pharma Sciences, LLC Receives Approval for NIPRIDE® RTU, (sodium nitroprusside) in 0.9% sodium chloride injection, 10mg / 50mL (200 mcg/mL), the First Ready to Use 200 mcg/mL sodium nitroprusside injection.
February 12, 2018 | Comments Off on EXELA Pharma Sciences, LLC Receives Approval for NIPRIDE® RTU, (sodium nitroprusside) in 0.9% sodium chloride injection, 10mg / 50mL (200 mcg/mL), the First Ready to Use 200 mcg/mL sodium nitroprusside injection.

Lenoir, NC February 9, 2018 – Exela Pharma Sciences, LLC (“Exela”) today announced that it received FDA approval for NIPRIDE® RTU (sodium nitroprusside) in 0.9% sodium chloride injection, 10mg/50mL (200 mcg/mL) as a supplement to the currently marketed NIPRIDE® RTU 50mg/100mL. NIPRIDE® RTU (sodium nitroprusside) is indicated for the immediate reduction of blood pressure of adult and pediatric patients. NIPRIDE® RTU is also indicated for producing controlled hypotension to reduce bleeding during surgery. NIPRIDE® RTU is also indicated for the treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure,  peripheral vascular resistance and mean
Read More